CANF.US Can Fite Biopharma Ltd ADR

Healthcare Biotechnology USA Stocks
1.42 USD
Close of Nov 13, 2026
1.42 7.90
Market cap
USD 4.30M
P/E
-
P/B
0.93x
ROE
-189.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CANF.US undervalued?

Graham number

The Graham number of Can Fite Biopharma Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Can Fite Biopharma Ltd ADR fundamental analysis

No fundamental analysis for Can Fite Biopharma Ltd ADR yet.

Can Fite Biopharma Ltd ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Can Fite Biopharma Ltd ADR

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the trea…

Full company profile